Ligand Pharmaceuticals reported $19.41M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Amgen USD 538M 33.04B Jun/2025
Arrowhead Research USD 138.14M 137.91M Jun/2025
Baxter International USD 683M 0 Dec/2024
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
GlaxoSmithKline GBP 4.15B 2.8B Jun/2025
Glaxosmithkline GBP 4.15B 2.8B Jun/2025
Insmed USD 211.11M 209.29M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
Ligand Pharmaceuticals USD 19.41M 19.39M Jun/2025
MacroGenics USD 63.21M 62.58M Jun/2025
Merck USD 1.79B 0 Mar/2025
Pacira USD 44.9M 44.85M Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Veracyte USD 78.32M 78.24M Jun/2025